All In Biotech

Drug Trial Radar · NCT06940830

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

A Low-interventional Study to Evaluate Long-term Effectiveness of Real-world Prophylactic Treatment With Efanesoctocog Alfa on Joint Health in People With Haemophilia A (ALTITUDE)

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

252

Actual

Start

May 21, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
Apr 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The rationale for this study is to further understand and describe the long-term prophylactic effectiveness of efanesoctocog alfa in preventing joint bleeds in a real-life setting.

Conditions

  • Hemophilia A

Interventions

  • Efanesoctocog alfaDrug

    Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized joint bleeding rate (AjBR) over the prospective observation period.Time frame: Enrolment to Month 12, 24 and 36

Locations

31 sites in 8 countries. Site status is shown where the registry gives one.

  • Sobi Investigational Site

    Zagreb, Croatia

  • Sobi Investigational Site

    Brno, Czechia

  • Sobi Investigational Site

    Ostrava, Czechia

  • Sobi Investigational Site

    Prague, Czechia

  • Sobi Investigational Site

    Bordeaux, France

  • Sobi Investigational Site

    Marseille, France

  • Sobi Investigational Site

    Montpellier, France

  • Sobi Investigational Site

    Nantes, France

  • Sobi Investigational Site

    Paris, France

  • Sobi Investigational Site

    Rennes, France

  • Sobi Investigational Site

    Rouen, France

  • Sobi Investigational Site

    Berlin, Germany

  • Sobi Investigational Site

    Bonn, Germany

  • Sobi Investigational Site

    Frankfurt am Main, Germany

  • Sobi Investigational Site

    Hamburg, Germany

  • Sobi Investigational Site

    Munich, Germany

  • Sobi Investigational Site

    Dublin, Ireland

  • Sobi Investigational Site

    Catania, Italy

  • Sobi Investigational Site

    Padua, Italy

  • Sobi Investigational Site

    Salerno, Italy

  • Sobi Investigational Site

    Turin, Italy

  • Sobi Investigational Site

    A Coruña, Spain

  • Sobi Investigational Site

    Barcelona, Spain

  • Sobi Investigational Site

    Málaga, Spain

  • Sobi Investigational Site

    Palma de Mallorca, Spain

  • Sobi Investigational Site

    Zaragoza, Spain

  • Sobi Investigational Site

    Salamanca, Castille and León, Spain

  • Sobi Investigational Site

    Birmingham, United Kingdom

  • Sobi Investigational Site

    Cardiff, United Kingdom

  • Sobi Investigational Site

    London, United Kingdom

  • Sobi Investigational Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.